IP Library Granted Patent US 8,884,060
Granted Patent B2
US 8,884,060 · App. 13/309,918 · Granted Nov 11, 2014

Process of preparing chiral diacylhydrazine ligands

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,884,060
App. No.
13/309,918
Granted
Nov 11, 2014
Kind
B2
Abstract

The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.

Claims (44)

1. A process for preparing a compound of Formula IV:

wherein:

A is optionally substituted aryl or optionally substituted heteroaryl;

B is 3,5-di-methylphenyl;

R 2 is tert-butyl; and

R 8 , R 9 , R 10 , R 11 and R 12 are hydrogen;

wherein the asymmetric carbon atom to which R 2 is attached is enantiomerically enriched in the R isomer

comprising:

a) reacting a compound of Formula V:

with a compound of Formula VI:

R 2 HC═N—NH—CO 2 R 7   Formula VI

wherein:

X and Y are independently O or NR wherein R is alkyl or aryl;

C a and C b are independently an asymmetric carbon atom of the S configuration;

R 14 and R 15 are independently alkyl or aryl;

R 13 is halo, hydrogen, alkyl, alkoxy or OSO 2 CF 3 ;

R 7 is alkyl, arylalkyl or aryl;

R 2 is tert-butyl and

R 8 , R 9 , R 10 , R 11 and R 12 are hydrogen;

to form a compound of Formula VII:

b) reducing the compound of Formula VII to form a compound of Formula VIII:

c) reacting the compound of Formula VIII with a compound of Formula B-CO-LG wherein B is 3,5-di-methylphenyl and LG is a leaving group to form a compound of Formula IX:

d) removing the R 7 CO 2 — group of the compound of Formula IX to form a compound of Formula X; and

e) reacting the compound of Formula X with a compound of Formula A-CO-LG wherein A is optionally substituted aryl or optionally substituted heteroaryl and LG is a leaving group, to form a compound of Formula IV selected from the group consisting of:

(R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide;

(R)-3,5-dimethyl-benzoic acid N′-benzoyl-N-(1-tert-butyl-butyl)-hydrazide;

(R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-methyl-benzoyl)-hydrazide;

(R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-fluoro-benzoyl)-hydrazide;

(R)-3,5-dimethyl-benzoic acid N-(2-bromo-benzoyl)-N-(1-tert-butyl-butyl)-hydrazide;

(R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(3-methyl-benzoyl)-hydrazide;

(R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(4-methyl-benzoyl)-hydrazide;

(R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-chloro-pyridine-3-carbonyl)-hydrazide;

(R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(6-chloro-pyridine-3-carbonyl)-hydrazide; and

(R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide.

2. The process of claim 1 , wherein said compound of Formula IV is (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide.

3. The process of claim 1 , wherein said compound of Formula IV is (R)-3,5-dimethyl-benzoic acid N′-benzoyl-N-(1-tert-butyl-butyl)-hydrazide.

4. The process of claim 1 , wherein said compound of Formula IV is (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-methyl-benzoyl)-hydrazide.

5. The process of claim 1 , wherein said compound of Formula IV is (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-fluoro-benzoyl)-hydrazide.

6. The process of claim 1 , wherein said compound of Formula IV is (R)-3,5-dimethyl-benzoic acid N′-(2-bromo-benzoyl)-N-(1-tert-butyl-butyl)-hydrazide.

7. The process of claim 1 , wherein said compound of Formula IV is (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(3-methyl-benzoyl)-hydrazide.

8. The process of claim 1 , wherein said compound of Formula IV is (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(4-methyl-benzoyl)-hydrazide.

9. The process of claim 1 , wherein said compound of Formula IV is (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-chloro-pyridine-3-carbonyl)-hydrazide.

10. The process of claim 1 , wherein said compound of Formula IV is (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(6-chloro-pyridine-3-carbonyl)-hydrazide.

11. The process of claim 1 , wherein said compound of Formula IV is (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide.

Assignments (1)
PATENT SECURITY AGREEMENT Recorded Sep 3, 2025
From: PRECIGEN, INC.; GENVEC LLC; PRECIGEN ACTOBIO, INC.; EXEMPLAR GENETICS, LLC
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 072828/0564 →